News

This product is the generic version of Hikma Maple Ltd.’s Robaxin®. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug

The findings were presented at the 53rd Annual Meeting of the American College of Neuropsychopharmacology (ACNP) held December 7-11 in Phoenix, Arizona. Dasotraline, a new chemical entity discovered

The multi-year research program will evaluate a novel approach to improve the function of the defective protein associated with cystic fibrosis, called CFTR. The program is investigating a

This product is the generic version of LASTACAFT (alcaftadine ophthalmic solution) 0.25%, which is indicated for the prevention of itching associated with allergic conjunctivitis. Wilshire believes that it

The recall is being initiated as a result of two complaints (one per lot) of particulate matter that was identified as a fragment of the frangible from the

Ovarian cancer patients who have no measurable disease following their initial standard surgery and chemotherapy treatments have an unmet need that may be served by the DPX-Survivac therapy.

The trial is designed to evaluate the efficacy and safety of revusiran in patients with FAC, which is one of the predominant clinical manifestations of TTR-mediated amyloidosis (ATTR).

Antimicrobial resistance seen in multidrug-resistant tuberculosis (MDR-TB) is one of the world’s most serious public health threats. MDR-TB is resistant to at least two of the four most

At the time of analysis, the median duration of response had not been reached with three of five responders on therapy for 11 months or more (range, 15